key: cord-1006126-zem77ui3
authors: Sofi-Mahmudi, Ahmad
title: Orofacial adverse effects of COVID-19 vaccines exist but are rare
date: 2021-06-25
journal: Evid Based Dent
DOI: 10.1038/s41432-021-0178-y
sha: 91420f5cfdc56c39dcbed3cca49da3b50bbacd2d
doc_id: 1006126
cord_uid: zem77ui3

Data sources The US Food and Drug Administration (FDA), Health Canada, European Medicines Agency (EMA)/European Commission and UK's Medicines and Healthcare products Regulatory Agency (MHRA). Study selection Product monographs, product information and consumer medicine information for the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines. Data extraction and synthesis Reported side/adverse/undesirable effects concerning the orofacial region were extracted and tabulated. Results There were rare reports of adverse events affecting the orofacial region for both vaccines in their pertaining documents, including acute peripheral facial paralysis (Bell's palsy), facial swelling and swelling of the lips, face or tongue associated with anaphylaxis. There was heterogeneity in the acknowledgement of vaccine-related adverse events in North America compared with Europe. Conclusions There are rare reports of orofacial adverse effects of two mRNA-based COVID-19 vaccines in their documents; however, there are inconsistencies in the description of these adverse effects in different countries.

With the COVID-19 pandemic emerging throughout the world in early 2020, many pharmaceutical companies in different countries tried to manufacture an effective vaccine against the SARS-CoV-2 virus which is responsible for the disease. After announcing the success of the clinical trials of some of these vaccines and regulatory approvals, countries started mass vaccination campaigns. Two of these early vaccines, BNT162b2 

Diagnosing the determinants of vaccine hesitancy in specific subgroups: The Guide to Tailoring Immunization Programmes (TIP)

Vaccine confidence in the time of COVID-19

Vaccine hesitancy: the next challenge in the fight against COVID-19

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

AstraZeneca vaccine: Blood clots are "extremely rare" and benefits outweigh risks, regulators conclude

Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine

Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns

Oral Side Effects of COVID-19 Vaccine